|
US6750348B1
(en)
|
1999-03-24 |
2004-06-15 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds
|
|
FR2793248B1
(fr)
|
1999-05-03 |
2001-06-29 |
Adir |
Nouveaux derives de 2,3-methano-aminoacides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
WO2000076512A1
(en)
|
1999-06-11 |
2000-12-21 |
Merck & Co., Inc. |
Cyclopentyl modulators of chemokine receptor activity
|
|
US6894063B2
(en)
*
|
2000-09-14 |
2005-05-17 |
Schering Corporation |
Substituted urea neuropeptide Y Y5 Receptor antagonists
|
|
WO2003037894A1
(en)
|
2001-11-02 |
2003-05-08 |
Glaxo Group Limited |
4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
|
|
US20040142416A1
(en)
|
2002-04-30 |
2004-07-22 |
Laipis Philip J. |
Treatment for phenylketonuria
|
|
WO2007030761A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Smithkline Beecham Corporation |
Acyclic 1,4-diamines and uses thereof
|
|
WO2007115232A2
(en)
|
2006-03-30 |
2007-10-11 |
Chemocentryx, Inc. |
Cxcr4 modulators
|
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
|
BRPI0721451A2
(pt)
|
2007-03-13 |
2014-03-25 |
Arete Therapeutics Inc |
Compostos de 4-piperidiniluréia como inibidores de epóxido hidrolase solúvel
|
|
FR2944206B1
(fr)
|
2009-04-09 |
2012-12-28 |
Sanofi Aventis |
Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
|
|
WO2011060397A1
(en)
|
2009-11-16 |
2011-05-19 |
Schering Corporation |
Substituted amino heterocycles useful as hiv antagonists
|
|
WO2011060396A1
(en)
|
2009-11-16 |
2011-05-19 |
Schering Corporation |
Aliphatic amines based heterocycles useful as hiv entry blockers
|
|
WO2012113103A1
(en)
|
2011-02-25 |
2012-08-30 |
Helsinn Healthcare S.A. |
Asymmetric ureas and medical uses thereof
|
|
CN104470914A
(zh)
|
2012-06-20 |
2015-03-25 |
桑多斯股份公司 |
替拉瑞韦和波普瑞韦或者其药学上可接受的盐或溶剂合物和中间产物包括经Mukaiyama羟醛加成制备的β-氨基酸的合成
|
|
WO2014144130A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Als Mountain Llc |
Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
|
|
US9783504B2
(en)
*
|
2013-07-09 |
2017-10-10 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibitors for the treatment of disease
|
|
TWI703130B
(zh)
|
2014-03-07 |
2020-09-01 |
瑞士商赫爾辛保健股份有限公司 |
對位取代的不對稱脲及其醫療用途
|
|
WO2016095089A1
(en)
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
AR103297A1
(es)
|
2014-12-30 |
2017-05-03 |
Forma Therapeutics Inc |
Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
|
|
CN117050032A
(zh)
*
|
2016-12-15 |
2023-11-14 |
阿瑞雅德制药公司 |
作为c-kit抑制剂的氨基噻唑化合物
|
|
WO2019040106A2
(en)
*
|
2017-08-21 |
2019-02-28 |
Acadia Pharmaceuticals Inc. |
COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
|
|
WO2019046303A1
(en)
*
|
2017-08-28 |
2019-03-07 |
The Trustees Of Columbia University In The City Of New York |
METHOD FOR PREDICTING PATIENT RESPONSE TO SLC MODULATOR PROCESSING
|
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
|
GB201809050D0
(en)
|
2018-06-01 |
2018-07-18 |
E Therapeutics Plc |
Modulators of tryptophan catabolism
|
|
EP3866798A4
(en)
|
2018-10-15 |
2022-07-13 |
Dana-Farber Cancer Institute, Inc. |
ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES
|
|
CN111978311B
(zh)
|
2019-05-21 |
2024-05-31 |
中国科学院上海有机化学研究所 |
一类细胞程序性坏死抑制剂及其制备方法和用途
|
|
AU2020308862B2
(en)
|
2019-06-28 |
2026-03-26 |
Research Triangle Institute |
Urea derivatives as CB1 allosteric modulators
|
|
BR112022010895A2
(pt)
|
2019-12-04 |
2022-09-06 |
Omeros Corp |
Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
|
|
BR112023015061A2
(pt)
|
2021-01-27 |
2023-10-03 |
Corteva Agriscience Llc |
Compostos antiparasitários
|
|
KR20230169979A
(ko)
|
2021-03-10 |
2023-12-18 |
다이스 몰레큘스 에스브이, 인크. |
알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
|
|
EP4304586A4
(en)
|
2021-03-10 |
2025-04-02 |
Jnana Therapeutics Inc. |
SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION
|
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
|
MX2024000357A
(es)
|
2021-07-07 |
2024-02-12 |
Incyte Corp |
Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
|
|
EP4376840A4
(en)
|
2021-07-28 |
2025-05-21 |
Nura Bio, Inc. |
SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
|
|
TW202321229A
(zh)
|
2021-08-18 |
2023-06-01 |
美商富曼西公司 |
殺真菌的取代的雜環化合物
|
|
WO2023023532A2
(en)
|
2021-08-18 |
2023-02-23 |
Chemocentryx, Inc. |
Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
|
|
CN117813307A
(zh)
|
2021-08-18 |
2024-04-02 |
新锐思生物制药股份有限公司 |
白介素-1受体相关激酶的双官能降解物及其治疗用途
|
|
WO2023079294A1
(en)
|
2021-11-05 |
2023-05-11 |
Sitryx Therapeutics Limited |
Phthalazine derivatives as pyruvate kinase modulators
|
|
JP2025500308A
(ja)
|
2021-12-22 |
2025-01-09 |
ジュニャーナ セラピューティクス インコーポレイテッド |
哺乳類ｓｌｃ６ａ１９機能の小分子阻害剤
|
|
EP4452982A1
(en)
|
2021-12-22 |
2024-10-30 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
|
US20250163022A1
(en)
|
2021-12-22 |
2025-05-22 |
Synnovation Therapeutics, Inc. |
Parp1 inhibitors
|
|
EP4452980A1
(en)
|
2021-12-22 |
2024-10-30 |
Chiesi Farmaceutici S.p.A. |
Triazolone derivative salt as neutrophil elastase inhibitor
|
|
MX2024007744A
(es)
|
2021-12-22 |
2024-07-01 |
Sitryx Therapeutics Ltd |
Derivados de ftalazina como moduladores de piruvato quinasa.
|
|
EP4452253A4
(en)
|
2021-12-23 |
2026-04-15 |
The Katholieke Univ Leuven |
2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD
|
|
WO2024015574A1
(en)
|
2022-07-14 |
2024-01-18 |
Jnana Therapeutics Inc. |
Small molecule inhibitors of mammalian slc6a19 function
|
|
EP4554584A2
(en)
|
2022-07-14 |
2025-05-21 |
Jnana Therapeutics Inc. |
Small molecule inhibitors of mammalian slc6a19 function
|
|
JP2025531160A
(ja)
|
2022-09-14 |
2025-09-19 |
ジュニャーナ セラピューティクス インコーポレイテッド |
Ｓｌｃ６ａ１９機能のスピロ置換ピペリジン阻害剤及び他のピペリジン阻害剤によるｐｋｕの処置
|
|
WO2024059005A1
(en)
|
2022-09-14 |
2024-03-21 |
Jnana Therapeutics Inc. |
Treating pku with correctors of mammalian slc6a19 function
|
|
AU2023342603A1
(en)
|
2022-09-14 |
2025-04-17 |
Jnana Therapeutics Inc. |
Dosing regimen for treating pku with a piperidine inhibitor of slc6a19 function
|
|
EP4622960A1
(en)
|
2022-11-22 |
2025-10-01 |
Maze Therapeutics, Inc. |
Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
|
|
EP4626420A1
(en)
|
2022-11-30 |
2025-10-08 |
Jnana Therapeutics Inc. |
Crystalline forms of a piperidine inhibitor of slc6a19 function
|
|
KR20260022325A
(ko)
|
2023-06-14 |
2026-02-19 |
제이나나 테라퓨틱스 인코포레이티드 |
Slc6a19 기능의 피페리딘 억제제
|
|
CN121666235A
(zh)
|
2023-08-11 |
2026-03-13 |
杰那医疗公司 |
Slc6a19功能的含双环杂芳基的哌啶抑制剂
|
|
TW202515556A
(zh)
|
2023-08-17 |
2025-04-16 |
美商杰那醫療公司 |
Ｓｌｃ６ａ１９功能之含萘基哌啶抑制劑
|